Praxis Precision Medicines Announces FDA Extends PDUFA Date To December 27, 2026 For Relutrigine Following Major Amendment Submission; No New Clinical Or Safety Concerns Cited

뉴스 본문을 불러오고 있어요.

Praxis Precision Medicines Announces FDA Extends PDUFA Date To December 27, 2026 For Relutrigine Following Major Amendment Submission; No New Clinical Or Safety Concerns Cited | 웨이프 WAPE

Praxis Precision Medicines Announces FDA Extends PDUFA Date To December 27, 2026 For Relutrigine Following Major Amendment Submission; No New Clinical Or Safety Concerns Cited

기사 요약

관련 종목

댓글 —